ArticleOncology letters2019
Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Invasive SpeciesFrontiers in pharmacology · 2022Pooled it
- Polydatin mitigates cigarette smoke-induced pulmonary apoptosis by regulating Bim via FoxO3 post-translational modifications and modulating the gut microenvironment.Biology direct · 2026Article
- Polydatin protects against leukemia by inducing apoptosis and activating autophagy via p38-MAPK pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Polydatin: A natural compound with multifaceted anticancer properties.Journal of traditional and complementary medicine · 2025Review
- Polydatin inhibits histone deacetylase 1 and shows an anti-angiogenic action in head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2024Article
- Article
- Targeting autophagy: polydatin's role in inducing cell death in AML.Frontiers in pharmacology · 2024Article
- Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.Cellular & molecular biology letters · 2023Review
- Article
- Uncovering the Anticancer Potential of Polydatin: A Mechanistic Insight.Molecules (Basel, Switzerland) · 2022Review
- Polydatin: Pharmacological Mechanisms, Therapeutic Targets, Biological Activities, and Health Benefits.Molecules (Basel, Switzerland) · 2022Review
- Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.PPAR research · 2022Review
- Polydatin Counteracts 5-Fluorouracil Resistance by Enhancing Apoptosis via Calcium Influx in Colon Cancer.Antioxidants (Basel, Switzerland) · 2021Article
- The emerging relationship between metabolism and DNA repair.Cell cycle (Georgetown, Tex.) · 2021Review
- Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent.Trends in pharmacological sciences · 2021Review
- FOXO1: a pivotal pioneer factor in oral squamous cell carcinoma.American journal of cancer research · 2021Review
- Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review).Frontiers in oncology · 2021Review
- Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.Biomolecules · 2020Review
- FOXO transcription factor family in cancer and metastasis.Cancer metastasis reviews · 2020Review
- The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polydatin, extracted from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.